IGH amplification in patients with B cell lymphoma unclassifiable, with features intermediate between diffuse large B cell lymphoma and Burkitt’s lymphoma

Biomarker Research

Michael Bellone¹  Ann-Leslie Zaslav²  Tahmeena Ahmed¹  Htien L Lee²  Yupo Ma¹  Youjun Hu¹ 

[1] Department of Pathology, Stony Brook University Medical Center, Stony Brook, NY 11794, USA

[2] Cytogenetics, Department of Pathology, Stony Brook University Medical Center, Stony Brook, NY 11794, USA

关键词: BCL2;    C-MYC;    IGH;    B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt’s lymphoma;   

Others  :  791706
DOI  :  10.1186/2050-7771-2-9

 received in 2014-02-06, accepted in 2014-04-14,  发布年份 2014

【 摘 要 】

B cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma (DLBCL) and Burkitt’s lymphoma (BL) (B-UNC/BL/DLBCL) is a new category of tumors that have features resembling both DLBCL and BL. These tumors have large and medium sized cells with greater irregularity of nuclei and more prominent nucleoli than BL. Approximately 35% to 50% have C-MYC rearrangements, although half are non-immunoglobulin variants. We identified six cases of B-UNC/BL/DLBCL with low-level IGH amplification. Four patients died with a median survival of 7 months (range, 6–20). In conclusion, to our knowledge low-level IGH amplification has not been previously described and should be evaluated for in this patient population.

【 授权许可】

   
2014 Bellone et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Kluin PM, Harris NL, Stein H, Leoncini L, et al.: B-cell lymphoma, unclassifiable, with features intermediate between large B-cell lymphoma and Burkitt lymphoma. In WHO classification of tumours of haematopoietic and lymphoid tissues. 4th edition. Edited by Swerdlow SH, Campo E, Harris NL. Lyon, France: IARC; 2008:265-266.
• [2]Schaeffer LG, Slovak ML, Campbell LJ: ISCN 2013: an International System for Human Cytogenetic Nomenclature. Unionville, CT: Karger; 2013.
• [3]Pinkel D, Gray JW, Trask B, van den Engh G, Fuscoe J, van Dekken H: Cytogenetic analysis by in situ hybridization with fluorescently labeled nucleic acid probes. Cold Spring Harb Symp Quant Biol 1986, 51:151-157.
• [4]Foot NJ, Dunn RG, Geoghegan H, Wilkins BS, Neat MJ: Fluorescence in situ hybridization analysis of formalin-fixed paraffin-embedded tissue sections in the diagnostic work-up of non-Burkitt high grade B-cell non-Hodgkin’s lymphoma: a single centre’s experience. J Clin Pathol 2011, 64:802-808.
• [5]Kodet R, Mrhalová M, Stejskalová E, Kabícková E: Burkitt lymphoma (BL): reclassification of 39 lymphomas diagnosed as BL or Burkitt-like lymphoma in the past based on immunohistochemistry and fluorescence in situ hybridization. Cesk Patol 2011, 47:106-114.
• [6]Perry AM, Crockett D, Dave BJ, Althof P, Winkler L, Smith LM, Aoun P, Chan WC, Fu K, Greiner TC, Bierman P, Gregory Bociek R, Vose JM, Armitage JO, Weisenburger DD: B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 cases. Br J Haematol 2013, 162:40-49.
• [7]Mossafa H, Damotte D, Jenabian A, Delarue R, Vincenneau A, Amouroux I, Jeandel R, Khoury E, Martelli JM, Samson T, Tapia S, Flandrin G, Troussard X: Non-Hodgkin’s lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis. Leuk Lymphoma 2006, 47:1885-1893.
• [8]Niitsu N, Okamoto M, Miura I, Hirano M: Clinical significance of 8q24/c-MYC translocation in diffuse large B-cell lymphoma. Cancer Sci 2009, 100:233-237.
• [9]Kanungo A, Medeiros LJ, Abruzzo LV, Lin P: Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol 2006, 19:25-33.
• [10]Li S, Lin P, Fayad LE, Lennon PA, Miranda RN, Yin CC, Lin E, Medeiros LJ: B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol 2012, 25:145-156.
• [11]Tauro S, Cochrane L, Lauritzsen GF, Baker L, Delabie J, Roberts C, Mahendra P, Holte H: Dose-intensified treatment of Burkitt lymphoma and B-cell lymphoma unclassifiable, (with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma) in young adults (<50 years): a comparison of two adapted BFM protocols. Am J Hematol 2010, 85:261-263.